Site menu
Menu
Looking for growth in 2020 and beyond? Here are the latest ASX growth stock ideas, stories and news from our team at Rask Media. We think it’s fair to say that Australia’s ASX growth stocks are some of the best in the world, given their potential for international growth and the fact that many Australian companies also offer their dividends with franking credits.
Pro Medicus Limited (ASX: PME) was a standout, adding 12.4%. The radiology imaging technology firm announced another $140 million ten year contract in the US as the business continues to scale quickly.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.45% to 7044.90.
At current prices, PXA shares have never been cheaper and appear undervalued on 26x FY25e P/E – estimates which only assume a partially success to its UK rollout and continued subdued Australian housing volumes.
The Pro Medicus Ltd (ASX:PME) share price is on watch after the healthcare imaging software ASX share announced a great win in Texas.
At 12 noon this Wednesday, you will get 5 of Scott’s ASX share ideas AND be able to ask us questions. All LIVE.
Another 4% fall in the price of iron ore was almost enough to drive the S&P/ASX200 (INDEXASX: XJO) lower, with the materials sector falling 0.7% to open the week.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.11% to 7076.50.
The key catalyst, of course, was the Fed meeting. While the Fed kept rates on hold as widely expected, the ‘dot plot’ of Fed policy expectations retained a further rate hike this year – and one less rate cut in 2024.
Up 42%, is Washington H. Soul Pattinson & Co. Ltd (ASX: SOL) a growth stock? Maybe, but probably not.
Pro Medicus Limited (ASX: PME) was a standout, adding 12.4%. The radiology imaging technology firm announced another $140 million ten year contract in the US as the business continues to scale quickly.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.45% to 7044.90.
At current prices, PXA shares have never been cheaper and appear undervalued on 26x FY25e P/E – estimates which only assume a partially success to its UK rollout and continued subdued Australian housing volumes.
The Pro Medicus Ltd (ASX:PME) share price is on watch after the healthcare imaging software ASX share announced a great win in Texas.
At 12 noon this Wednesday, you will get 5 of Scott’s ASX share ideas AND be able to ask us questions. All LIVE.
Another 4% fall in the price of iron ore was almost enough to drive the S&P/ASX200 (INDEXASX: XJO) lower, with the materials sector falling 0.7% to open the week.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.11% to 7076.50.
The key catalyst, of course, was the Fed meeting. While the Fed kept rates on hold as widely expected, the ‘dot plot’ of Fed policy expectations retained a further rate hike this year – and one less rate cut in 2024.
Up 42%, is Washington H. Soul Pattinson & Co. Ltd (ASX: SOL) a growth stock? Maybe, but probably not.
Want to level-up your analytical skills and investing insights but don’t know where to start? We can help. Join 40,000+ Australian investors on our mailing list today and we’ll send you our favourite podcasts, courses, resources, investment articles and podcasts every week. Delivered to your inbox every Sunday morning. Grab a coffee and let Owen and the team bring you the best investment insights every week.
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) and Target Market Determination before making a decision to acquire any financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.
“Rask Invest” is considered a financial product and has a Product Disclosure Statement (PDS) and Target Market Determination (TMD), issued by InvestSMART. These documents can be accessed on the Rask Invest website. Please seek professional advice before making any investment decision with respect to Rask Invest.
© Rask Australia 2024
